ABSTRACT
A rapid, novel spectrofluorimetric method to determine epristeride (EP) in biological fluids and a pharmaceutical formulation was developed, based on the fact that fluorescence intensity of L-tryptophan could be quenched by EP in the medium of pH ? 9.0. The various factors influencing fluorescence quenching were discussed. The quenching mechanism was investigated with the quenching type, synchronous fluorescence spectra and quantum efficiency. Under the optimized conditions, fluorescence quenching value (ΔF ? FL-tryptophan-FEP-L-tryptophan) showed a good linear relationship with the EP concentration ranging from 0.4 to 12.0μg/mL. The linearity, recovery and limit of detection demonstrated that the proposed method was suitable for EP determination in biological fluids and EP tablets. The method was successfully applied to the analysis of EP in real samples and the obtained results were in good agreement with the results of the official method.
ABSTRACT
Objective To evaluate the security and efficacy of combination of epristeride and terazosin for treatment of benign prostatic hyperplasia (BPH). Method One hundred and eighty-four patients with BPH were treated by epristeride for 6 months and terazosin for 1 month, the efficacy and complication were observed. Results After 6 months treated, compared with before treated, the common symptoms improved, the residual urine decreased 20.74ml, maximum flow rate increased 3.76 ml/s, prostate volume grown downwards 6.70cm3 and the quality of life raised apparently(Pall＜0.05 ). Condusion Combinationof epristeride and terazosin for treatment of BPH is safe and effective.
ABSTRACT
Objective To discuss the effect of the concentration of dihydrotestostemne(DHT)in prostatic tissue treating by 5a-reductase inhibitors.Methods One hundred and twenty-one pros-tatic samples were selected:group A1(18 patients treating by epristeride for 1 month),group A2(22patients treating by epristeride for 3 months),group B1(23 patients treating by finasteride for 1 month),group B2(21 patients treating by finasteride for 3 months),group C(25 patients non-treating by 5α-reductase inhibitors),group D(12 samples of prostate from body).The concentration of DHT was measured by radio-immunity,Results The concentration of DHT in prostate declined after treating by epristeride 1 month and 3 months(66.21%and 70.60%,P＜0.05).The decline of the concentration of DHT in prostate after treating by epristeride 1 month was larger than 3 months(P＜0.05).The concentration of DHT in prostate declined after treating by finasteride 1 month and 3 months.There Was no signiificant difference of the concentration of DHT in prostate after treating by finasteride 1 month and 3 months.Conclusions The concentration of DHT in prostate can be declined after treating by epristeride and finasteride.The decline of the concentration of DHT is consistent aftertrealring by epristeride.The decline of the concentration of DHT is considerable between epristeride and finasteride.
ABSTRACT
Objective Study the efficacy and safety of epristeride, a new uncompetitive 5?-reductase inhibitor, in the treatment of benign prostatic hyperplasia(BPH). Methods A multicentral opened clinical trial was conducted. 2 006 BPH patients were enrolled in the trial, in which 5mg epristeride was orally administered twice a day. Results After 4 months therapy, IPSS score was averagely decreased 6.12(28.8%) ( P